Table 2

Univariate and multivariate analysis of DFS for the three different groups

CharacteristicsNeoadjuvant chemoimmunotherapyNeoadjuvant chemotherapyTreatment naïve
Univariate analysis
P value
Multivariate analysis
P value OR
(95% CI)
Univariate analysis
P value
Multivariate analysis
P value
OR (95% CI)
Univariate analysis
P value
Multivariate analysis
P value OR
(95% CI)
GenderMale or female0.6640.6550.124
Age<61 or ≥610.7080.1830.355
Smoking historySmoker, ex-smoker or never smoker0.3800.4530.739
HistologySquamous cell carcinomas, Adenocarcinoma, or large cell carcinoma0.7750.7650.186
N stageN0 or N1-20.0160.037 0.259
(0.073 to 0.923)
0.0010.003 0.177
(0.056 to 0.558)
0.0180.034 0.341
(0.126 to 0.922)
Neoadjuvant therapy no of cycles2 or >20.3790.345
TLS maturationLow maturationor high maturation0.0050.014 4.527
(1.351 to 15.167)
0.884 38.84
(0.001 to 4.870)
0.0200.035 2.988
(1.079 to 8.276)
TLS abundance0.0350.0540.0030.9650.0470.104
Score 0111
Score 10.059 5.764
(0.937 to 35.452)
0.882 8.113
(0.001 to 6.853)
0.026 10.509
(1.326 to 83.259)
Score 20.027 10.410
(1.300 to 83.363)
0.885 5.813
(0.001 to 4.952)
0.068 8.428
(0.854 to 82.213)
Score 30.995 1.007
(0.082 to 12.413)
0.928 6.785
(0.001 to 1.330)
0.496 2.622
(0.164 to 42.011)
  • DFS, disease-free survival; TLS, tertiary lymphoid structures.